Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment

Senores Pharmaceuticals reported consolidated Q2FY27 revenue of ₹192.33 crore, up 24.9% YoY, with EBITDA surging 38% YoY to ₹58 crore and PAT rising 21.5%

Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment

Senores Pharmaceuticals Ltd · Change in Auditor · 29 Oct 2026, 7:39 pm

Senores Pharmaceuticals Q2FY27 Results and Joint Statutory Auditor Appointment Senores Pharmaceuticals reported consolidated Q2FY27 revenue of ₹192.33 crore, up 24.9% YoY, with EBITDA surging 38% YoY to ₹58 crore and PAT rising 21.5% YoY to ₹36.60 crore. For H1FY27, revenue climbed 30.0% YoY to ₹372.54 crore, while PAT reached ₹67.05 crore, up 30.7% YoY. Operating cash flow improved to ₹29.22 crore in H1FY27. Management guided for 30–40% revenue growth and 50–60% PAT growth in FY27. Additionally, the board approved appointing M/s Talati and Talati LLP as Joint Statutory Auditors for FY27–FY31.

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements